For the chance to live longer without progression, strive earlier for PLUVICTORY.
The first and only FDA-approved, PSMA-targeted therapy to significantly delay progression in mHSPC & mCRPC.
rPFS (primary end point) in the PSMAddition and PSMAfore trials:
In PSMA+ mHSPC (PSMAddition): Final analysis: PLUVICTO® + ARPI reduced the risk of radiographic progression or death by 33% vs ARPI (HR=0.67 [95% Cl, 0.55-0.82]).* Primary analysis: PLUVICTO + ARPI reduced the risk of radiographic progression or death by 28% vs ARPI (HR=0.72 [95% CI, 0.58-0.90]; P=0.002)†
In PSMA+ mCRPC after only 1 ARPI (PSMAfore): Updated exploratory analysis: Median rPFS was 11.6 months with PLUVICTO vs 5.6 months with a change in ARPI (HR=0.49 [95% CI, 0.39-0.61]).‡ Primary analysis: 9.3 months vs 5.6 months (HR=0.41 [95% Cl, 0.29-0.56]; P<0.0001)
In PSMA+ mHSPC and PSMA+ mCRPC,
Choose PLUVICTO at the earliest eligible opportunity
PLUVICTO: For your patients across the continuum of metastatic prostate cancer
PLUVICTO in mHSPC
For patients with mHSPC (+ ARPI) at any point after diagnosis1,2
PLUVICTO in mCRPC
For patients with mCRPC after only 1 ARPI, received at any point in the prostate cancer journey1,3,§
§For patients considered appropriate to delay taxane-based chemotherapy.1
Choose PLUVICTO: Proven in three phase 3 clinical trials.¶ And ~30K patients treated since FDA approval1-5,#
ARPI, androgen receptor pathway inhibitor; HR, hazard ratio; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; NE, not estimable; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive; rPFS, radiographic progression-free survival.
*Median rPFS was not reached in the PLUVICTO + ARPI arm vs 48.5 months (95% CI, 40.5-NE) in the ARPI arm. Final rPFS analysis was performed with a median follow-up period of 37.7 months vs the primary analysis at 23.6 months. This analysis was not controlled for Type-I error.2,6
†Median rPFS was not reached in either arm.1
‡Exploratory rPFS analysis was performed with a median follow-up period of 24 months vs the primary analysis at 7 months. This analysis was not controlled for Type-I error.3
¶PLUVICTO was studied in 1 clinical trial of mHSPC and 2 clinical trials of mCRPC.1,3,4
#Based on data from March 2026.5